CD46, chemotaxis and MS-are these linked?

Chemotaxis: Types, Clinical Significance, and Mathematical Models

Volumn , Issue , 2011, Pages 85-108

  Choileain, Siobhan Ni ^a,b   Stephen, Jillian ^b   Weller, Belinda ^c   Astier, Anne L ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85016791232     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (116)

1. Feldmann, M; Steinman, L. Design of effective immunotherapy for human autoimmunity. Nature, 2005, 435, 612-619.
2. Hafler, DA; Slavik, JM; Anderson, DE; O’Connor, KC; De Jager, P; Baecher-Allan, C. Multiple sclerosis. Immunol Rev, 2005, 204, 208-231.
3. Hohlfeld, R; Wekerle, H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc Natl Acad Sci, U S A, 2004, 101 Suppl 2, 14599-14606.
4. Miller, D. Multiple sclerosis: new insights and therapeutic progress. Lancet Neurol, 2007, 6, 5-6.
5. Yoshie, O; Imai, T; Nomiyama, H. Chemokines in immunity. Adv Immunol, 2001, 78, 57-110.
6. Astier, A; Trescol-Biemont, M. C; Azocar, O; Lamouille, B; RabourdinCombe, C; Cutting edge: CD46, a new costimulatory molecule for T cells, that induces p120CBL and LAT phosphorylation. J Immunol, 2000, 164, 6091-6095.
7. Zaffran, Y; Destaing, O; Roux, A; Ory, S; Nheu, T; Jurdic, P; Rabourdin-Combe, C; Astier, A. L; CD46/CD3 costimulation induces morphological changes of human T cells and activation of Vav, Rac, and extracellular signal-regulated kinase mitogen-activated protein kinase. J Immunol, 2001, 167, 6780-6785.
8. Marie, JC; Astier, AL; Rivailler, P; Rabourdin-Combe, C; Wild, TF; Horvat, B. Linking innate and acquired immunity: divergent role of CD46 cytoplasmic domains in T cell induced inflammation. Nat Immunol, 2002, 3, 659-666.
9. Kemper, C; Chan, AC; Green, JM; Brett, KA; Murphy, KM; Atkinson, JP. Activation of human CD4(+) cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature, 2003, 421, 388-392.
10. Grossman, WJ; Verbsky, JW; Tollefsen, BL; Kemper, C; Atkinson, JP; Ley, TJ; Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood, 2004, 104, 2840-2848.
11. Vaknin-Dembinsky, A; Murugaiyan, G; Hafler, DA; Astier, AL; Weiner, HL. Increased IL-23 secretion and altered chemokine production by dendritic cells upon CD46 activation in patients with multiple sclerosis. J Neuroimmunol, 2008, 195, 140-145.
12. Astier, AL; Meiffren, G; Freeman, S; Hafler, DA; Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J Clin Invest, 2006, 116, 3252-3257.
13. Astier, AL. T-cell regulation by CD46 and its relevance in multiple sclerosis. Immunology, 2008, 124, 149-154.
14. Martinez-Forero, I; Garcia-Munoz, R; Martinez-Pasamar, S; Inoges, S; Lopez-Diaz de Cerio, A; Palacios, R; Sepulcre, J; Moreno, B; Gonzalez, Z; Fernandez-Diez, B; Melero, I; Bendandi, M; Villoslada, P. IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur J Immunol, 2008, 38, 576-586.
15. Alford, SK; Longmore, GD; Stenson, WF; Kemper, C. CD46-induced immunomodulatory CD4+ T cells express the adhesion molecule and chemokine receptor pattern of intestinal T cells. J Immunol, 2008. 181, 2544-2555.
16. Adorini, L. Immunotherapeutic approaches in multiple sclerosis. J Neurol Sci, 2004, 223, 13-24.
17. McQualter, JL; Bernard, CC; Multiple sclerosis: a battle between destruction and repair. J Neurochem, 2007, 100, 295-306.
18. Hafler, DA; Compston, A; Sawcer, S; Lander, ES; Daly, MJ; De Jager, PL; de Bakker, PI; Gabriel, SB; Mirel, DB; Ivinson, AJ; Pericak-Vance, MA; Gregory, SG; Rioux, JD; McCauley, JL; Haines, JL; Barcellos, LF; Cree, B; Oksenberg, JR; Hauser, SL. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med, 2007, 357, 851-862.
19. Ramagopalan, SV; Maugeri, NJ; Handunnetthi, L; Lincoln, MR; Orton, SM; Dyment, DA; Deluca, GC; Herrera, BM; Chao, MJ; Sadovnick, AD; Ebers, GC; Knight, JC. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet, 2009, 5, e1000369.
20. Hamann, I; Zipp, F; Infante-Duarte, C. Therapeutic targeting of chemokine signaling in Multiple Sclerosis. J Neurol Sci, 2008, 274, 31-38.
21. Zlotnik, A; Yoshie, O; Chemokines: a new classification system and their role in immunity. Immunity, 2000, 12, 121-127.
22. Luster, AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med, 1998 338, 436-445.
23. Murdoch, C; Finn, A. Chemokine receptors and their role in inflammation and infectious diseases. Blood, 2000, 95, 3032-3043.
24. Moser, B. T-cell memory, the importance of chemokine-mediated cell attraction. Curr Biol, 2006, 16, R504-507.
25. Sallusto, F; Lanzavecchia, A; Mackay, CR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today, 1998, 19, 568-574.
26. Sallusto, F; Kremmer, E; Palermo, B; Hoy, A; Ponath, P; Qin, S; Forster, R; Lipp, M; Lanzavecchia, A. Switch in chemokine receptor expression upon TCR stimulation reveals novel homing potential for recently activated T cells. Eur J Immunol, 1999, 29, 2037-2045.
27. Ebert, LM; McColl, SR. Coregulation of CXC chemokine receptor and CD4 expression on T lymphocytes during allogeneic activation. J Immunol, 2001, 166, 4870-4878.
28. Culley, FJ; Pennycook, AM; Tregoning, JS; Hussell, T; Openshaw, PJ. Differential chemokine expression following respiratory virus infection reflects Th1- or Th2-biased immunopathology. J Virol, 2006, 80, 4521-4527.
29. Contento, RL; Molon, B; Boularan, C; Pozzan, T; Manes, S; Marullo, S; Viola, A. CXCR4-CCR5: a couple modulating T cell functions. Proc Natl Acad Sci U S A, 2008, 105, 10101-10106.
30. Whiting, D; Hsieh, G; Yun, JJ; Banerji, A; Yao, W; Fishbein, MC; Belperio, J; Strieter, RM; Bonavida, B; Ardehali, A. Chemokine monokine induced by IFN-gamma/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production. J Immunol, 2004, 172, 7417-7424.
31. Marelli-Berg, FM; Okkenhaug, K; Mirenda, V. A two-signal model for T cell trafficking. Trends Immunol, 2007, 28, 267-273.
32. Bromley, SK; Peterson, DA; Gunn, MD; Dustin, ML. Cutting edge: hierarchy of chemokine receptor and TCR signals regulating T cell migration and proliferation. J Immunol, 2000, 165, 15-19.
33. Nanki, T; Lipsky, PE. Cutting edge: stromal cell-derived factor-1 is a costimulator for CD4+ T cell activation. J Immunol, 2000, 164, 5010-5014.
34. Kumar, A; Humphreys, TD; Kremer, KN; Bramati, PS; Bradfield, L; Edgar, CE; Hedin, KE. CXCR4 physically associates with the T cell receptor to signal in T cells. Immunity, 2006, 25, 213-224.
35. Kremer, KN; Kumar, A; Hedin, KE. Haplotype-independent costimulation of IL-10 secretion by SDF-1/CXCL12 proceeds via AP-1 binding to the human IL-10 promoter. J Immunol, 2007, 178, 1581-1588.
36. Moore, CA; Milano, SK; Benovic, JL. Regulation of receptor trafficking by GRKs and arrestins. Annu Rev Physiol, 2007, 69, 451-482.
37. Bromley, SK; Mempel, TR; Luster, AD. Orchestrating the orchestrators, chemokines in control of T cell traffic. Nat Immunol, 2008, 9, 970-980.
38. Sorensen, TL; Roed, H; Sellebjerg, F. Chemokine receptor expression on B cells and effect of interferon-beta in multiple sclerosis. J Neuroimmunol, 2002, 122, 125-131.
39. Sorensen, TL; Sellebjerg, F. Selective suppression of chemokine receptor CXCR3 expression by interferon-beta1a in multiple sclerosis. Mult Scler, 2002, 8, 104-107.
40. Sellebjerg, F; Krakauer, M; Hesse, D; Ryder, LP; Alsing, I; Jensen, PE; Koch-Henriksen, N; Svejgaard, A; Soelberg Sorensen, P; Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation. Eur J Neurol, 2009, 16, 1291-1298.
41. Ransohoff, RM. Chemokines and chemokine receptors: standing at the crossroads of immunobiology and neurobiology. Immunity, 2009, 31, 711-721.
42. Karpus, WJ; Lukacs, NW; McRae, BL; Strieter, RM; Kunkel, SL; Miller, SD. An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol, 1995, 155, 5003-5010.
43. Bartosik-Psujek, H; Stelmasiak, Z. The levels of chemokines CXCL8, CCL2 and CCL5 in multiple sclerosis patients are linked to the activity of the disease. Eur J Neurol, 2005, 12, 49-54.
44. Miyagishi, R; Kikuchi, S; Fukazawa, T; Tashiro, K. Macrophage inflammatory protein-1 alpha in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological diseases. J Neurol Sci, 1995, 129, 223-227.
45. Glabinski, AR; Bielecki, B; O’Bryant, S; Selmaj, K; Ransohoff, RM. Experimental autoimmune encephalomyelitis, CC chemokine receptor expression by trafficking cells. J Autoimmun, 2002, 19, 175-181.
46. Huang, DR; Wang, J; Kivisakk, P; Rollins, BJ; Ransohoff, RM. Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J Exp Med, 2001, 193, 713-726.
47. Sorensen, TL; Ransohoff, RM; Strieter, RM; Sellebjerg, F. Chemokine CCL2 and chemokine receptor CCR2 in early active multiple sclerosis. Eur J Neurol 2004, 11, 445-449.
48. Iarlori, C; Reale, M; De Luca, G; Di Iorio, A; Feliciani, C; Tulli, A; Conti, P; Gambi, D; Lugaresi, A. Interferon beta-1b modulates MCP-1 expression and production in relapsing-remitting multiple sclerosis. J Neuroimmunol, 2002, 123, 170-179.
49. Moreira, MA; Tilbery, CP; Monteiro, LP; Teixeira, MM; Teixeira, AL. Effect of the treatment with methylprednisolone on the cerebrospinal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis. Acta Neurol Scand, 2006, 114, 109-113.
50. Narikawa, K; Misu, T; Fujihara, K; Nakashima, I; Sato, S; Itoyama, Y. CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis. J Neuroimmunol, 2004, 149, 182-186.
51. Calderon, TM; Eugenin, EA; Lopez, L; Kumar, SS; Hesselgesser, J; Raine, CS; Berman, JW. A role for CXCL12 (SDF-1alpha) in the pathogenesis of multiple sclerosis, regulation of CXCL12 expression in astrocytes by soluble myelin basic protein. J Neuroimmunol, 2006, 177, 27-39.
52. Balashov, KE; Rottman, JB; Weiner, HL; Hancock, WW. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A, 1999, 96, 6873-6878.
53. Julia, E; Edo, MC; Horga, A; Montalban, X; Comabella, M. Differential susceptibility to apoptosis of CD4+T cells expressing CCR5 and CXCR3 in patients with MS. Clin Immunol, 2009, 133, 364-374.
54. Mahad, DJ; Lawry, J; Howell, SJ; Woodroofe, MN. Longitudinal study of chemokine receptor expression on peripheral lymphocytes in multiple sclerosis, CXCR3 upregulation is associated with relapse. Mult Scler, 2003, 9, 189-198.
55. Royal, W; 3rd, Mia, Y; Li, H; Naunton, K; Peripheral blood regulatory, T. cell measurements correlate with serum vitamin D levels in patients with multiple sclerosis. J Neuroimmunol, 2009, 213, 135-141.
56. Reboldi, A; Coisne, C; Baumjohann, D; Benvenuto, F; Bottinelli, D; Lira, S; Uccelli, A; Lanzavecchia, A; Engelhardt, B; Sallusto, F. C-C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat Immunol, 2009, 10, 514-523.
57. Graham, KL; Zabel, BA; Loghavi, S; Zuniga, LA; Ho, PP; Sobel, RA; Butcher, EC. Chemokine-like receptor-1 expression by central nervous system-infiltrating leukocytes and involvement in a model of autoimmune demyelinating disease. J Immunol, 2009, 183, 6717-6723.
58. Trebst, C; Staugaitis, SM; Kivisakk, P; Mahad, D; Cathcart, MK; Tucky, B; Wei, T; Rani, MR; Horuk, R; Aldape, KD; Pardo, CA; Lucchinetti, CF; Lassmann, H; Ransohoff, RM. CC chemokine receptor 8 in the central nervous system is associated with phagocytic macrophages. Am J Pathol, 2003, 162, 427-438.
59. Vroon, A; Heijnen, CJ; Kavelaars, A. GRKs and arrestins, regulators of migration and inflammation. J Leukoc Biol, 2006, 80, 1214-1221.
60. Thelen, M; Stein, JV. How chemokines invite leukocytes to dance. Nat Immunol, 2008, 9, 953-959.
61. Sallusto, F; Baggiolini, M. Chemokines and leukocyte traffic. Nat Immunol, 2008. 9, 949-952.
62. Viola, A; Molon, B; Contento, RL. Chemokines: coded messages for T-cell missions. Front Biosci, 2008, 13, 6341-6353.
63. Aragay, AM; Ruiz-Gomez, A; Penela, P; Sarnago, S; Elorza, A; Jimenez-Sainz, MC; Mayor, F. Jr; G protein-coupled receptor kinase 2 (GRK2): mechanisms of regulation and physiological functions. FEBS Lett, 1998, 430, 37-40.
64. Pitcher, JA; Freedman, NJ; Lefkowitz, RJ. G protein-coupled receptor kinases. Annu Rev Biochem, 1998, 67, 653-692.
65. Ribas, C; Penela, P; Murga, C; Salcedo, A; Garcia-Hoz, C; JuradoPueyo, M; Aymerich, I; Mayor, F. Jr; The G protein-coupled receptor kinase (GRK) interactome, role of GRKs in GPCR regulation and signaling. Biochim Biophys Acta, 2007, 1768, 913-922.
66. De Blasi, A; Parruti, G; Sallese, M. Regulation of G protein-coupled receptor kinase subtypes in activated T lymphocytes. Selective increase of beta-adrenergic receptor kinase 1 and 2. J Clin Invest, 1995, 95, 203-210.
67. Ramer-Quinn, DS; Baker, RA; Sanders, VM; Activated, T. helper, 1 and T helper 2 cells differentially express the beta-2-adrenergic receptor, a mechanism for selective modulation of T helper 1 cell cytokine production. J Immunol, 1997, 159, 4857-4867.
68. Vroon, A; Kavelaars, A; Limmroth, V; Lombardi, MS; Goebel, MU; Van Dam, AM; Caron, MG; Schedlowski, M; Heijnen, CJ; G protein-coupled receptor kinase 2 in multiple sclerosis and experimental autoimmune encephalomyelitis. J Immunol, 2005, 174, 4400-4406.
69. Vroon, A; Heijnen, CJ; Lombardi, MS; Cobelens, PM; Mayor, F; Jr; Caron, MG; Kavelaars, A. Reduced GRK2 level in T cells potentiates chemotaxis and signaling in response to CCL4. J Leukoc Biol, 2004, 75, 901-909.
70. Oppermann, M; Mack, M; Proudfoot, AE; Olbrich, H. Differential effects of CC chemokines on CC chemokine receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the CCR5 carboxyl terminus. J Biol Chem, 1999, 274, 8875-8885.
71. Balabanian, K; Levoye, A; Klemm, L; Lagane, B; Hermine, O; Harriague, J; Baleux, F; Arenzana-Seisdedos, F; Bachelerie, F. Leukocyte analysis from WHIM syndrome patients reveals a pivotal role for GRK3 in CXCR4 signaling. J Clin Invest, 2008, 118, 1074-1084.
72. Lombardi, MS; Kavelaars, A; Schedlowski, M; Bijlsma, JW; Okihara, KL; Van de Pol, M; Ochsmann, S; Pawlak, C; Schmidt, RE; Heijnen, CJ. Decreased expression and activity of G-protein-coupled receptor kinases in peripheral blood mononuclear cells of patients with rheumatoid arthritis. Faseb J, 1999, 13, 715-725.
73. Vroon, A; Lombardi, MS; Kavelaars, A; Heijnen, CJ. Changes in the G-protein-coupled receptor desensitization machinery during relapsing-progressive experimental allergic encephalomyelitis. J Neuroimmunol, 2003, 137, 79-86.
74. Giorelli, M; Livrea, P; Defazio, G; Iacovelli, L; Capobianco, L; Picascia, A; Sallese, M; Martino, D; Aniello, MS; Trojano, M; De Blasi, A. Interferon beta-1a counteracts effects of activation on the expression of G-protein-coupled receptor kinases 2 and 3, beta-arrestin-1, and regulators of G-protein signalling 2 and 16 in human mononuclear leukocytes. Cell Signal, 2002, 14, 673-678.
75. Lombardi, MS; Kavelaars, A; Penela, P; Scholtens, EJ; Roccio, M; Schmidt, RE; Schedlowski, M; Mayor, F; Jr; Heijnen, CJ. Oxidative stress decreases G protein-coupled receptor kinase 2 in lymphocytes via a calpain-dependent mechanism. Mol Pharmacol, 2002, 62, 379-388.
76. Seya, T; Hirano, A; Matsumoto, M; Nomura, M; Ueda, S; Human membrane cofactor protein (MCP, CD46), multiple isoforms and functions. Int J Biochem Cell Biol, 1999, 31, 1255-1260.
77. Cattaneo, R. Four viruses, two bacteria, and one receptor: membrane cofactor protein (CD46) as pathogens’ magnet. J Virol, 2004, 78, 4385-4388.
78. Riley-Vargas, RC; Gill, DB; Kemper, C; Liszewski, MK; Atkinson, JP. CD46, expanding beyond complement regulation. Trends Immunol, 2004, 25, 496-503.
79. Russell, SM; Loveland, BE; Johnstone, RW; Thorley, BR; McKenzie, IF. Functional characterisation of alternatively spliced CD46 cytoplasmic tails. Transplant Proc, 1992, 24, 2329-2330.
80. Johnstone, RW; Russell, SM; Loveland, BE; McKenzie, IF. Polymorphic expression of CD46 protein isoforms due to tissue-specific RNA splicing. Mol Immunol, 1993, 30, 1231-1241.
81. Rudd, CE; Schneider, H. Unifying concepts in CD28, ICOS and CTLA4 co-receptor signalling. Nat Rev Immunol, 2003, 3, 544-556.
82. Sharpe, AH; Freeman, GJ. The B7-CD28 superfamily. Nat Rev Immunol, 2002, 2, 116-126.
83. Jimenez-Perianez, A; Ojeda, G; Criado, G; Sanchez, A; Pini, E; Madrenas, J; Rojo, J. M; Portoles, P. Complement regulatory protein Crry/p65-mediated signaling in T lymphocytes, role of its cytoplasmic domain and partitioning into lipid rafts. J Leukoc Biol 2005, 78, 1386-1396.
84. Gaglia, JL; Mattoo, A; Greenfield, EA; Freeman, GJ; Kuchroo, VK; Characterization of endogenous Chinese hamster ovary cell surface molecules that mediate T cell costimulation. Cell Immunol, 2001, 213, 83-93.
85. Fernandez-Centeno, E; de Ojeda, G; Rojo, JM; Portoles, P; Crry/p65, a membrane complement regulatory protein, has costimulatory properties on mouse T cells. J Immunol, 2000, 164, 4533-4542.
86. Morgan, BP; Marchbank, KJ; Longhi, MP; Harris, CL; Gallimore, AM. Complement: central to innate immunity and bridging to adaptive responses. Immunol Lett, 2005, 97, 171-179.
87. Kemper, C; Atkinson, JP. T-cell regulation: with complements from innate immunity. Nat Rev Immunol, 2007, 7, 9-18.
88. Longhi, MP; Harris, CL; Morgan, BP; Gallimore, A; Holding, T. cells in check--a new role for complement regulators? Trends Immunol, 2006, 27, 102-108.
89. Sanchez, A; Feito, MJ; Rojo, JM. CD46-mediated costimulation induces a Th1-biased response and enhances early TCR/CD3 signaling in human CD4+ T lymphocytes. Eur J Immunol, 2004, 34, 2439-2448.
90. Oliaro, J; Pasam, A; Waterhouse, NJ; Browne, KA; Ludford-Menting, MJ; Trapani, JA; Russell, SM. Ligation of the cell surface receptor, CD46, alters T cell polarity and response to antigen presentation. Proc Natl Acad Sci, U S A, 2006, 103, 18685-18690.
91. Russell, S. CD46: a complement regulator and pathogen receptor that mediates links between innate and acquired immune function. Tissue Antigens, 2004, 64, 111-118.
92. Lee, SW; Bonnah, RA; Higashi, DL; Atkinson, JP; Milgram, SL; So, M. CD46 is phosphorylated at tyrosine 354 upon infection of epithelial cells by Neisseria gonorrhoeae. J Cell Biol, 2002, 156, 951-957.
93. Kurita-Taniguchi, M; Hazeki, K; Murabayashi, N; Fukui, A; Tsuji, S; Matsumoto, M; Toyoshima, K; Seya, T. Molecular assembly of CD46 with CD9, alpha3-beta1 integrin and protein tyrosine phosphatase SHP-1 in human macrophages through differentiation by GM-CSF. Mol Immunol, 2002, 38, 689-700.
94. Karp, CL; Wysocka, M; Wahl, LM; Ahearn, JM; Cuomo, PJ; Sherry, B; Trinchieri, G; Griffin, DE. Mechanism of suppression of cell-mediated immunity by measles virus [published erratum appears in Science 1997 Feb 21;275(5303), 1053]. Science, 1996, 273, 228-231.
95. Schnorr, JJ; Xanthakos, S; Keikavoussi, P; Kampgen, E; ter Meulen, V; Schneider-Schaulies, S. Induction of maturation of human blood dendritic cell precursors by measles virus is associated with immunosuppression. Proc Natl Acad Sci, U S A, 1997, 94, 5326-5331.
96. Smith, A; Santoro, F; Di Lullo, G; Dagna, L; Verani, A; Lusso, P. Selective suppression of IL-12 production by human herpesvirus 6. Blood, 2003, 102, 2877-2884.
97. Wong, TC; Yant, S; Harder, BJ; Korte-Sarfaty, J; Hirano, A. The cytoplasmic domains of complement regulatory protein CD46 interact with multiple kinases in macrophages. J Leukoc Biol, 1997, 62, 892-900.
98. Ludford-Menting, MJ; Thomas, SJ; Crimeen, B; Harris, LJ; Loveland, BE; Bills, M; Ellis, S; Russell, SM. A functional interaction between CD46 and DLG4: a role for DLG4 in epithelial polarization. J Biol Chem, 2002, 277, 4477-4484.
99. Hirano, A; Yang, Z; Katayama, Y; Korte-Sarfaty, J; Wong, TC. Human CD46 enhances nitric oxide production in mouse macrophages in response to measles virus infection in the presence of gamma interferon: dependence on the CD46 cytoplasmic domains [In Process Citation]. J Virol, 1999, 73, 4776-4785.
100. Wang, G; Liszewski, M; Chan, A; Atkinson, J. Membrane cofactor protein (MCP; CD46): isoform-specific tyrosine phosphorylation. J Immunol, 2000, 164, 1839-1846.
101. Joubert, PE; Meiffren, G; Gregoire, IP; Pontini, G; Richetta, C; Flacher, M; Azocar, O; Vidalain, PO; Vidal, M; Lotteau, V; Codogno, P; Rabourdin-Combe, C; Faure, M. Autophagy induction by the pathogen receptor CD46. Cell Host Microbe, 2009, 6, 354-366.
102. Shusta, EV; Zhu, C; Boado, RJ; Pardridge, WM. Subtractive expression cloning reveals high expression of CD46 at the blood-brain barrier. J Neuropathol Exp Neurol, 2002, 61, 597-604.
103. Johansson, L; Rytkonen, A; Bergman, P; Albiger, B; Kallstrom, H; Hokfelt, T; Agerberth, B; Cattaneo, R; Jonsson, AB. CD46 in meningococcal disease. Science, 2003, 301, 373-375.
104. Meeuwsen, S; Persoon-Deen, C; Bsibsi, M; Bajramovic, JJ; Ravid, R; De Bolle, L; van Noort, JM. Modulation of the cytokine network in human adult astrocytes by human herpesvirus-6A. J Neuroimmunol, 2005, 164, 37-47.
105. Noe, KH; Cenciarelli, C; Moyer, SA; Rota, PA; Shin, ML. Requirements for measles virus induction of RANTES chemokine in human astrocytoma-derived U373 cells. J Virol 1999. 73, 3117-3124.
106. Soldan, SS; Fogdell-Hahn, A; Brennan, MB; Mittleman, BB; Ballerini, C; Massacesi, L; Seya, T; McFarland, HF; Jacobson, S. Elevated serum and cerebrospinal fluid levels of soluble human herpesvirus type 6 cellular receptor, membrane cofactor protein, in patients with multiple sclerosis. Ann Neurol, 2001, 50, 486-493.
107. Fogdell-Hahn, A; Soldan, SS; Shue, S; Akhyani, N; Refai, H; Ahlqvist, J; Jacobson, S. Co-purification of soluble membrane cofactor protein (CD46) and human herpesvirus 6 variant A genome in serum from multiple sclerosis patients. Virus Res, 2005, 110, 57-63.
108. Tuke, PW; Hawke, S; Griffiths, PD; Clark, DA. Distribution and quantification of human herpesvirus 6 in multiple sclerosis and control brains. Mult Scler, 2004, 10, 355-359.
109. Astier, AL; Hafler, DA. Abnormal Tr1 differentiation in multiple sclerosis. J Neuroimmunol, 2007, 191, 70-78.
110. Ma, A; Xiong, Z; Hu, Y; Qi, S; Song, L; Dun, H; Zhang, L; Lou, D; Yang, P; Zhao, Z; Wang, X; Zhang, D; Daloze, P; Chen, H. Dysfunction of IL-10-producing type 1 regulatory T cells and CD4+CD25+ regulatory T cells in a mimic model of human multiple sclerosis in Cynomolgus monkeys. International Immunopharmacology, 2009, 9, 599-608.
111. Kivisakk, P; Tucky, B; Wei, T; Campbell, JJ; Ransohoff, RM. Human cerebrospinal fluid contains CD4+ memory T cells expressing gut- or skin-specific trafficking determinants: relevance for immunotherapy. BMC Immunol, 2006, 7, 14.
112. Yednock, TA; Cannon, C; Fritz, LC; Sanchez-Madrid, F; Steinman, L; Karin, N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature, 1992, 356, 63-66.
113. Brocke, S; Piercy, C; Steinman, L; Weissman, IL; Veromaa, T. Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc Natl Acad Sci, U S A 1999, 96, 6896-6901.
114. Kanwar, JR; Harrison, JE; Wang, D; Leung, E; Mueller, W; Wagner, N; Krissansen, GW. Beta7 integrins contribute to demyelinating disease of the central nervous system. J Neuroimmunol, 2000, 103, 146-152.
115. Davenport, RJ; Munday, JR. Alpha4-integrin antagonism-an effective approach for the treatment of inflammatory diseases? Drug Discov Today, 2007, 12, 569-576.
116. Mellergard, J; Edstrom, M; Vrethem, M; Ernerudh, J; Dahle, C. Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid. Mult Scler., 16, 208-217.